CorMedix (CRMD) Return on Sales (2013 - 2026)

CorMedix has reported Return on Sales for 12 years, with the latest figure at 0.0% in Q4 2025.

• Quarterly Return on Sales fell 1.0% year-over-year to 0.0% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 0.0% (up 1.0% YoY) and the FY2025 annual result came in at 0.0%, up 1.0% from the prior year.
• Return on Sales eased to 0.0% in Q4 2025 per CRMD's latest filing, from 0.01% in the prior quarter.
• Over five years, Return on Sales peaked at 0.01% in Q3 2025 and troughed at 10.69% in Q1 2022.
• A 4-year average of 2.59% and a median of 1.71% in 2021 frame the typical range for Return on Sales.
• The widest YoY moves for Return on Sales: up 208 bps in 2022, down 873 bps in 2022.
• Over 4 years, Return on Sales stood at 1.71% in 2021, then sank by 61 bps to 2.76% in 2022, then surged by 100 bps to 0.0% in 2024, then plunged by 121 bps to 0.0% in 2025.
• According to Business Quant data, Return on Sales over the past three periods registered 0.0%, 0.01%, and 0.0% for Q4 2025, Q3 2025, and Q2 2025 respectively.